Characteristics of 57 follicular lymphoma patients studied
Patient . | Cyclin B1* . | Age, y . | Sex . | Stage . | Hemoglobin level, g/L . | FLIPI . | WHO grade . | Ki-67† . | Cause of death . | Follow-up, mo . | Treatment in temporal order‡ . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 11.4 | 81 | F | IIA | 102 | 1 | 3A | 3 | Colon cancer | 15 | KNOSPE |
| 2 | 11.8 | 68 | F | IIIA | 123 | 3 | 2 | 1 | Lymphoma | 56 | KNOSPE, CHOPx3, MIME |
| 3 | 17.7 | 42 | M | IA | 160 | 0 | 2 | 1 | Alive | 82 + | RT, rituximab |
| 4 | 26.7 | 49 | F | IIIA | 124 | 2 | 2 | 2 | Alive | 65 + | KNOSPE |
| 5 | 26.8 | 76 | M | IA | 172 | 1 | 2 | 1 | Alive | 87 + | No treatment |
| 6 | 28.1 | 67 | M | IA | 159 | 1 | 2 | 1 | Alive | 84 + | RT |
| 7 | 30.6 | 61 | F | IIA | 146 | 1 | 1 | 0 | Lymphoma | 51 | KNOSPE, RT, CNOPx5 + MTX, LD-ACOP-B |
| 8 | 32.7 | 83 | M | IVB | 127 | 2 | 2 | 1 | Lymphoma | 8 | CHOPx6, RT |
| 9 | 34.2 | 28 | F | IIIA | 143 | 2 | 2 | 1 | Lymphoma | 56 | KNOSPE, RT, rituximab, fludarabine, CHOPx5, RT |
| 10 | 34.3 | 42 | M | IVA | 125 | 2 | 2 | 0 | Lymphoma | 89 | Flu/Cycl, CHOPx3, MIME, RT, gemcitabine |
| 11 | 34.5 | 60 | M | IVA | 115 | 4 | 1 | 0 | Alive | 53 + | Rituximab, CHV(O)Px6, RT, KNOSPE, MIME, Flu/Cycl |
| 12 | 35.9 | 53 | F | IIIA | 133 | 1 | 1 | 1 | Lymphoma | 80 | KNOSPE, CHOPx8, Flu/Cycl, MIME |
| 13 | 36.0 | 75 | M | IIIB | 153 | 3 | 2 | 1 | Lymphoma | 44 | CHOPx8, KNOSPE, ENAD |
| 14 | 36.7 | 77 | M | IVA | 111 | 5 | 3B | 3 | Lymphoma | 7 | CHOPx6 |
| 15 | 40.4 | 59 | F | IA | 124 | 0 | 2 | 1 | Lymphoma | 55 | RT, CHOPx8, ENAD, MIME |
| 16 | 40.6 | 57 | F | IVA | 138 | 1 | 1 | 1 | Lymphoma | 81 | KNOSPE, CHOPx6, rituximab, RT, Flu/Cycl |
| 17 | 43.0 | 75 | M | IIIA | 142 | 4 | 2 | 3 | Lymphoma | 41 | KNOSPE |
| 18 | 43.0 | 82 | F | IA | 118 | 2 | 2 | 1 | Lymphoma | 64 | KNOSPE |
| 19 | 46.6 | 66 | M | IVA | 135 | 2 | 1 | 0 | Lymphoma | 10 | Prednimustine, CHOPx2, RT-CEP |
| 20 | 47.0 | 79 | M | IIIB | 109 | 4 | 2 | 1 | Lymphoma | 8 | KNOSPE |
| 21 | 47.9 | 73 | M | IIIA | 172 | 4 | 1 | 1 | Lymphoma | 95 | KNOSPE |
| 22 | 47.9 | 60 | F | IA | 133 | 0 | 2 | 1 | Alive | 63 + | No treatment |
| 23 | 48.1 | 43 | F | IIIA | 118 | 2 | 2 | 1 | Alive | 20 + | No treatment |
| 24 | 50.7 | 45 | M | IIIA | 154 | 1 | 2 | 1 | Alive | 50 + | No treatment |
| 25 | 51.1 | 68 | F | IVB | 145 | 4 | 1 | 0 | Alive | 67 + | CHOP×8, KNOSPE, MIME |
| 26 | 51.8 | 47 | F | IVA | 136 | 1 | 2 | 2 | Alive | 72 + | KNOSPE |
| 27 | 52.6 | 56 | F | IVB | 139 | 1 | 1 | 0 | Lymphoma | 82 | CdA, KNOSPE |
| 28 | 54.1 | 61 | M | IA | 159 | 1 | 3A | 2 | Alive | 59 + | RT |
| 29 | 59.0 | 57 | F | IVA | 135 | 1 | 2 | 1 | Alive | 87 + | CHOPx1, RT |
| 30 | 63.1 | 28 | M | IVB | 114 | 3 | 3B | 3 | Alive | 65 + | CHOPx7 + SCT |
| 31 | 64.9 | 56 | M | IA | 147 | 0 | 1 | 1 | Alive | 56 + | No treatment |
| 32 | 68.3 | 43 | F | IVA | 142 | 3 | 2 | 1 | Alive | 112 + | CdA |
| 33 | 68.7 | 61 | F | IVA | 140 | 2 | 3B | 2 | Lymphoma | 54 | CHOPx2, CHVPx6 |
| 34 | 74.4 | 60 | F | IVA | 134 | 2 | 2 | 1 | Alive | 72 + | Chlorambucil, rituximab |
| 35 | 77.4 | 85 | F | IIA | 128 | 2 | 3B | 3 | Lymphoma | 38 | CHOPx5, gemcitabine |
| 36 | 80.2 | 56 | F | IVA | 140 | 1 | 1 | 1 | Alive | 29 + | No treatment |
| 37 | 81.5 | 59 | M | IIIA | 158 | 1 | 1 | 0 | Alive | 58 + | No treatment |
| 38 | 84.4 | 78 | F | IIIA | 147 | 3 | 2 | 1 | Alive | 117 + | CHOPx4 |
| 39 | 85.0 | 80 | M | IVB | 84 | 4 | 1 | 1 | Lymphoma | 1 | No treatment |
| 40 | 86.3 | 71 | F | IA | 144 | 1 | 2 | 1 | Alive | 56 + | RT |
| 41 | 88.7 | 44 | F | IVA | 140 | 2 | 2 | 1 | Alive | 54 + | No treatment |
| 42 | 88.8 | 70 | F | IA | 127 | 1 | 2 | 1 | Alive | 70 + | RT |
| 43 | 90.6 | 72 | M | IVA | 133 | 3 | 2 | 1 | Lymphoma | 43 | KNOSPE, CHOPx6 |
| 44 | 90.7 | 46 | M | IVB | 145 | 1 | 2 | 2 | Alive | 63 + | Rituximab + interferon alfa |
| 45 | 96.0 | 37 | F | IIB | 135 | 0 | 2 | 1 | Alive | 57 + | CHOPx3 |
| 46 | 104.6 | 56 | F | IIIA | 156 | 1 | 2 | 1 | Alive | 28 + | Chlorambucil, rituximab |
| 47 | 105.1 | 34 | M | IA | 160 | 0 | 2 | 1 | Alive | 65 + | RT |
| 48 | 105.6 | 54 | F | IVA | 137 | 1 | 2 | 1 | Alive | 53 + | Rituximab, chlorambucil, CHOPx6 |
| 49 | 119.8 | 54 | F | IIIA | 135 | 1 | 2 | 1 | Alive | 63 + | CHOPx6, MIME, rituximab |
| 50 | 130.8 | 61 | F | IIA | 136 | 2 | 3B | 3 | Alive | 68 + | CHOPx6 |
| 51 | 153.0 | 47 | M | IIIA | 97 | 2 | 3B | 3 | Alive | 82 + | EPOCHx8 |
| 52 | 153.5 | 67 | F | IA | 137 | 2 | 3A | 3 | Alive | 58 + | RT |
| 53 | 173.2 | 54 | M | IIB | 140 | 0 | 2 | 1 | Alive | 81 + | Prednimustin, chlorambucil, prednisone, fludarabine |
| 54 | 175.4 | 56 | M | IIA | 127 | 0 | 3B | 3 | Alive | 31 + | CHOPx5 |
| 55 | 181.8 | 64 | M | IIIB | 126 | 2 | 3B | 3 | Alive | 70 + | CHOPx7 |
| 56 | 200.6 | 69 | F | IA | 132 | 2 | 3B | 3 | Alive | 81 + | RT, CHOPx8 |
| 57 | 246.8 | 77 | M | IA | 151 | 1 | 3B | 3 | Cardiac | 48 | RT |
Patient . | Cyclin B1* . | Age, y . | Sex . | Stage . | Hemoglobin level, g/L . | FLIPI . | WHO grade . | Ki-67† . | Cause of death . | Follow-up, mo . | Treatment in temporal order‡ . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 11.4 | 81 | F | IIA | 102 | 1 | 3A | 3 | Colon cancer | 15 | KNOSPE |
| 2 | 11.8 | 68 | F | IIIA | 123 | 3 | 2 | 1 | Lymphoma | 56 | KNOSPE, CHOPx3, MIME |
| 3 | 17.7 | 42 | M | IA | 160 | 0 | 2 | 1 | Alive | 82 + | RT, rituximab |
| 4 | 26.7 | 49 | F | IIIA | 124 | 2 | 2 | 2 | Alive | 65 + | KNOSPE |
| 5 | 26.8 | 76 | M | IA | 172 | 1 | 2 | 1 | Alive | 87 + | No treatment |
| 6 | 28.1 | 67 | M | IA | 159 | 1 | 2 | 1 | Alive | 84 + | RT |
| 7 | 30.6 | 61 | F | IIA | 146 | 1 | 1 | 0 | Lymphoma | 51 | KNOSPE, RT, CNOPx5 + MTX, LD-ACOP-B |
| 8 | 32.7 | 83 | M | IVB | 127 | 2 | 2 | 1 | Lymphoma | 8 | CHOPx6, RT |
| 9 | 34.2 | 28 | F | IIIA | 143 | 2 | 2 | 1 | Lymphoma | 56 | KNOSPE, RT, rituximab, fludarabine, CHOPx5, RT |
| 10 | 34.3 | 42 | M | IVA | 125 | 2 | 2 | 0 | Lymphoma | 89 | Flu/Cycl, CHOPx3, MIME, RT, gemcitabine |
| 11 | 34.5 | 60 | M | IVA | 115 | 4 | 1 | 0 | Alive | 53 + | Rituximab, CHV(O)Px6, RT, KNOSPE, MIME, Flu/Cycl |
| 12 | 35.9 | 53 | F | IIIA | 133 | 1 | 1 | 1 | Lymphoma | 80 | KNOSPE, CHOPx8, Flu/Cycl, MIME |
| 13 | 36.0 | 75 | M | IIIB | 153 | 3 | 2 | 1 | Lymphoma | 44 | CHOPx8, KNOSPE, ENAD |
| 14 | 36.7 | 77 | M | IVA | 111 | 5 | 3B | 3 | Lymphoma | 7 | CHOPx6 |
| 15 | 40.4 | 59 | F | IA | 124 | 0 | 2 | 1 | Lymphoma | 55 | RT, CHOPx8, ENAD, MIME |
| 16 | 40.6 | 57 | F | IVA | 138 | 1 | 1 | 1 | Lymphoma | 81 | KNOSPE, CHOPx6, rituximab, RT, Flu/Cycl |
| 17 | 43.0 | 75 | M | IIIA | 142 | 4 | 2 | 3 | Lymphoma | 41 | KNOSPE |
| 18 | 43.0 | 82 | F | IA | 118 | 2 | 2 | 1 | Lymphoma | 64 | KNOSPE |
| 19 | 46.6 | 66 | M | IVA | 135 | 2 | 1 | 0 | Lymphoma | 10 | Prednimustine, CHOPx2, RT-CEP |
| 20 | 47.0 | 79 | M | IIIB | 109 | 4 | 2 | 1 | Lymphoma | 8 | KNOSPE |
| 21 | 47.9 | 73 | M | IIIA | 172 | 4 | 1 | 1 | Lymphoma | 95 | KNOSPE |
| 22 | 47.9 | 60 | F | IA | 133 | 0 | 2 | 1 | Alive | 63 + | No treatment |
| 23 | 48.1 | 43 | F | IIIA | 118 | 2 | 2 | 1 | Alive | 20 + | No treatment |
| 24 | 50.7 | 45 | M | IIIA | 154 | 1 | 2 | 1 | Alive | 50 + | No treatment |
| 25 | 51.1 | 68 | F | IVB | 145 | 4 | 1 | 0 | Alive | 67 + | CHOP×8, KNOSPE, MIME |
| 26 | 51.8 | 47 | F | IVA | 136 | 1 | 2 | 2 | Alive | 72 + | KNOSPE |
| 27 | 52.6 | 56 | F | IVB | 139 | 1 | 1 | 0 | Lymphoma | 82 | CdA, KNOSPE |
| 28 | 54.1 | 61 | M | IA | 159 | 1 | 3A | 2 | Alive | 59 + | RT |
| 29 | 59.0 | 57 | F | IVA | 135 | 1 | 2 | 1 | Alive | 87 + | CHOPx1, RT |
| 30 | 63.1 | 28 | M | IVB | 114 | 3 | 3B | 3 | Alive | 65 + | CHOPx7 + SCT |
| 31 | 64.9 | 56 | M | IA | 147 | 0 | 1 | 1 | Alive | 56 + | No treatment |
| 32 | 68.3 | 43 | F | IVA | 142 | 3 | 2 | 1 | Alive | 112 + | CdA |
| 33 | 68.7 | 61 | F | IVA | 140 | 2 | 3B | 2 | Lymphoma | 54 | CHOPx2, CHVPx6 |
| 34 | 74.4 | 60 | F | IVA | 134 | 2 | 2 | 1 | Alive | 72 + | Chlorambucil, rituximab |
| 35 | 77.4 | 85 | F | IIA | 128 | 2 | 3B | 3 | Lymphoma | 38 | CHOPx5, gemcitabine |
| 36 | 80.2 | 56 | F | IVA | 140 | 1 | 1 | 1 | Alive | 29 + | No treatment |
| 37 | 81.5 | 59 | M | IIIA | 158 | 1 | 1 | 0 | Alive | 58 + | No treatment |
| 38 | 84.4 | 78 | F | IIIA | 147 | 3 | 2 | 1 | Alive | 117 + | CHOPx4 |
| 39 | 85.0 | 80 | M | IVB | 84 | 4 | 1 | 1 | Lymphoma | 1 | No treatment |
| 40 | 86.3 | 71 | F | IA | 144 | 1 | 2 | 1 | Alive | 56 + | RT |
| 41 | 88.7 | 44 | F | IVA | 140 | 2 | 2 | 1 | Alive | 54 + | No treatment |
| 42 | 88.8 | 70 | F | IA | 127 | 1 | 2 | 1 | Alive | 70 + | RT |
| 43 | 90.6 | 72 | M | IVA | 133 | 3 | 2 | 1 | Lymphoma | 43 | KNOSPE, CHOPx6 |
| 44 | 90.7 | 46 | M | IVB | 145 | 1 | 2 | 2 | Alive | 63 + | Rituximab + interferon alfa |
| 45 | 96.0 | 37 | F | IIB | 135 | 0 | 2 | 1 | Alive | 57 + | CHOPx3 |
| 46 | 104.6 | 56 | F | IIIA | 156 | 1 | 2 | 1 | Alive | 28 + | Chlorambucil, rituximab |
| 47 | 105.1 | 34 | M | IA | 160 | 0 | 2 | 1 | Alive | 65 + | RT |
| 48 | 105.6 | 54 | F | IVA | 137 | 1 | 2 | 1 | Alive | 53 + | Rituximab, chlorambucil, CHOPx6 |
| 49 | 119.8 | 54 | F | IIIA | 135 | 1 | 2 | 1 | Alive | 63 + | CHOPx6, MIME, rituximab |
| 50 | 130.8 | 61 | F | IIA | 136 | 2 | 3B | 3 | Alive | 68 + | CHOPx6 |
| 51 | 153.0 | 47 | M | IIIA | 97 | 2 | 3B | 3 | Alive | 82 + | EPOCHx8 |
| 52 | 153.5 | 67 | F | IA | 137 | 2 | 3A | 3 | Alive | 58 + | RT |
| 53 | 173.2 | 54 | M | IIB | 140 | 0 | 2 | 1 | Alive | 81 + | Prednimustin, chlorambucil, prednisone, fludarabine |
| 54 | 175.4 | 56 | M | IIA | 127 | 0 | 3B | 3 | Alive | 31 + | CHOPx5 |
| 55 | 181.8 | 64 | M | IIIB | 126 | 2 | 3B | 3 | Alive | 70 + | CHOPx7 |
| 56 | 200.6 | 69 | F | IA | 132 | 2 | 3B | 3 | Alive | 81 + | RT, CHOPx8 |
| 57 | 246.8 | 77 | M | IA | 151 | 1 | 3B | 3 | Cardiac | 48 | RT |
Relative expression of RNA of probe set 34736_at
Immunohistochemistry Ki-67: 0 indicates less than 10%; 1, 10% to 30%; 2, 30% to 50%; and 3, more than 50% cells positive
KNOSPE indicates chlorambucil, prednisone; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; MIME, mitoguazone, ifosfamide, methotrexate, etoposide; RT, radiotherapy; CNOP, cyclophosphamide, mitoxantrone, vincristine, prednisone; MTX, methotrexate; LD-ACOP-B, low-dose doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin; Flu/Cycl, fludarabine, cyclophosphamide; CHVP, cyclophosphamide, doxorubicin, teniposide, prednisone; ENAD, etoposide, mitoxantrone, cytarabine, prednisone; RT-CEP, lomustine, etoposide, chlorambucil, prednisone; CdA, cladribine; EPOCH, etoposide, cyclophosphamide, doxorubicin, vincristine, prednisone; and SCT, stem cell transplantation